High costs and the novelty and complexity of new therapies such as gene therapy present social determinants of health and ...

A decision is expected in the fourth quarter of 2025.

Cost is a barrier to care for chronic and rare diseases, so financial assistance is way to lower that barrier and help people ...

In January 2023, the Brukinsa, a next-generation BTK inhibitor, received FDA approval for chronic lymphocytic leukemia (CLL).

In mice with human Merkel cell carcinoma, pyrvinium pamoate significantly reduced tumor growth, potentially offering a new ...

Digital pharmacy solutions can help brick and mortar locations become more efficient, according to Sarah Thomas, VP of sales ...

Cigna Healthcare’s medical care ratio increased to 82.2% in the first quarter compared with 79.9% in the first quarter of ...

Effective July 1, 2025, CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies.

Treating hidradenitis suppurativa is complex and often requires taking a number of medications, including antibiotics, ...

Payers and providers, often depicted as rivals, are on the same side when it comes to the 340B program that allows some ...

The new research center at the University of Michigan and Oregon Health & Science University intends to develop a clinical ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...